Anita W. Asgar, MD, MSc, FRCPC, FACC
Dr Anita Asgar is an Interventional Cardiologist working at the Montreal Heart Institute since 2009. Originally from Newfoundland, Dr. Asgar completed her medical school and Internal Medicine Residency at Memorial University (1995-2002), and Cardiology training at Dalhousie University. She then completed a two-year fellowship in Interventional Cardiology at the Institut de Cardiologie de Montreal, followed by a fellowship in Structural and Congenital Intervention at the Royal Brompton Hospital in London, England as well as a fellowship in Cardiac Magnetic Resonance Imaging. She has a master’s degree in Biomedical Sciences from the Universite de Montreal with a focus in cost-effectiveness of transcatheter technology.
Dr. Anita Asgar is a full-time staff Interventional Cardiologist at the Montreal Heart Institute, and Associate Professor of Medicine at the Universite de Montreal. She specializes in transcatheter valve interventions, congenital interventions and cardiac MRI. Dr. Asgar was Co-Chair of the Canadian TAVR Guidelines and chairs the Working Group for Transcatheter Valve Therapy Quality Indicators in Canada. She has led the publication of two national quality reports for TAVR in Canada in 2016 and 2019 and was the Co-Chair of the Canadian Position statement for TAVR in 2019. She is the lead cardiologist for the transcatheter mitral/tricuspid valve program at the Montreal Heart Institute. Her research interests include the treatment and management of valvular heart disease and cost-effectiveness analysis and she is currently the Director of Transcatheter Valve Therapy Research at the Montreal Heart Institute.
Javed Butler, MD, MPH, MBA
Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson Mississippi. He is also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.
He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and Master in Business Administration from Emory University.
Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, U.S. Food & Drug Administration, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Dr. Butler has authored more than 700 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.
Richard Cook, BSc, MSc, MD, FRCSC
Dr. Richard Cook is a cardiac surgeon in Vancouver. He is the director of robotically-assisted and minimal-access cardiac surgery at Vancouver General Hospital. In addition to this, he is actively involved in the transcatheter valve repair and replacement programs in Vancouver. He is the outgoing chair of the cardiac surgery exam board at the Royal College of Physicians and Surgeons of Canada, and plans to use his extra free time to continue building an organic garlic farm.
Justin Ezekowitz, MBBCh, MSc, FRCPC
Dr. Justin Ezekowitz is a Professor of Medicine in the Division of Cardiology, Director of Cardiovascular Research, and Co-Director of the Canadian VIGOUR Centre at the University of Alberta. He is a cardiologist at the University of Alberta Hospital and Mazankowski Alberta Heart Institute. His research and clinical focus is on heart failure. He is involved in numerous clinical trials in heart failure as a site investigator, and on the steering or executive committee for several multicenter international trials. He is also involved in the design leadership and implementation of several investigator-initiated trials funded through governmental and non-governmental research agencies. In addition, he works with population health, registry-data and other data sources on clinically applicable research using advanced data analytics around health system change and disease risk.
Bonnie Ky, MD, MSCE
Bonny Ky is a tenured Associate Professor of Medicine and Epidemiology and physician scientist at the University of Pennsylvania. Her fundamental goals are to gain insight into the underlying mechanisms and predictors of cancer therapy cardiotoxicity, and translating this understanding to the clinical care of patients. She leads a highly active NIH-funded translational research program in cardio-oncology and is the PI of multiple investigator-initiated cohort studies and clinical trials focused on the study of the cardiotoxic effects of doxorubicin, trastuzumab, anti-angiogenic tyrosine kinase inhibitors, androgen deprivation therapy, and radiation therapy in breast, renal cell, prostate and lung cancer, and lymphoma patients. Her programmatic objectives are to understand how we can improve cardiovascular outcomes in cancer patients by determining individual patient risk, through detailed phenotyping of clinical characteristics, the social determinants of health, biologic markers, and echocardiography-derived measures of myocardial mechanics and function. She also serves as the Director for the Penn Center for Quantitative Echocardiography and is the Founding Director of the Penn Cardio-Oncology Translational Center of Excellence where she has built a strong, multi-disciplinary collaborative network comprised of highly successful basic, translational, and clinical researchers. She is an invited member of many cardio-oncology expert consensus and research groups within the NIH, FDA, American Society of Clinical Oncology, American College of Cardiology, American Heart Association, and European Society of Cardiology focused on advancing our understanding of cardiovascular disease in the growing cancer population. She is the Inaugural Editor-in-Chief of JACC: CardioOncology, and has successfully launched this important scientific and clinical resource. She has specialized expertise in cardio-oncology, epidemiology, the study of biomarkers, and imaging tools in order to understand cardiac remodeling, function, and risk prediction.
Guillaume Marquis-Gravel, MD, FRCPC
Dr. Guillaume Marquis-Gravel is an interventional cardiologist at the Montreal Heart Institute, and an assistant professor at Université de Montréal since 2020. He is a Junior 1 clinical-scientist of the Fonds de la Recherche du Québec – Santé (FRQS). He completed his medical training (M.D.), a Masters in Biomedical Sciences (M.Sc., with Honors), a residency in internal medicine, and a residency in adult cardiology (with Honors) at the Université de Montréal. He then completed a 1-year clinical fellowship in interventional cardiology at Duke University (Durham, NC, United States), followed by a 2-year clinical research fellowship at the Duke Clinical Research Institute. He is the primary author or a co-author of 65 peer-reviewed publications, including in the New England Journal of Medicine, JAMA Cardiology, the Journal of the American College of Cardiology, and Circulation, and of 4 book chapters, and has been part of the primary panel of the Canadian Cardiovascular Society guidelines on antiplatelet therapy. He is an associate editor of the Canadian Journal of Cardiology. His main research interests revolve around the antithrombotic management of acute and chronic coronary artery disease, and in the development of innovative clinical trial methods.
Mathew S. Mauer, MD
Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus.
Dr. Maurer received a B.S. in biomedical science as part of the seven-year medical school program at CCNY – The Sophie Davis School of Biomedical Education, where he was awarded the Belle Zeller Scholarship. He received his M.D. degree from Mount Sinai School of Medicine and graduated Alpha Omega Alpha. He completed training in internal medicine and cardiology at NewYork Presbyterian Hospital and was Chief Medical Resident.
Dr. Maurer’s work focuses on evaluating age related changes in cardiovascular physiology in order to elucidate the mechanism that underlie the higher prevalence and incidence of cardiovascular disease in older individuals. In much of his research he has focused on the following cardiovascular syndromes – syncope, falls and their relationship to disordered blood pressure regulation; heart failure in the setting of a preserved ejection fraction including hypertrophic cardiomyopathy and cardiac amyloidosis. He has received funding from the National Institute on Aging and National Heart, Lung and Blood Institute to support his research activities.
He has published over 270 articles including peer reviewed manuscripts, reviews and book chapters. He was Chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organization dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately afflict older adults.
Shamir Mehta, MD, MSc, FRCPC, FACC, FESC
Dr. Shamir Mehta is the Douglas Holder Endowed Chair in Interventional Cardiology and a Professor of Medicine at McMaster University. He is Director of the Interventional Cardiology program at Hamilton Health Sciences and Senior Scientist at the Population Health Research Institute in Hamilton, Canada. He graduated from the University of Toronto’s Faculty of Medicine where he also completed internal medicine and cardiology training, followed by an interventional cardiology fellowship at the University Health Network. He completed a research fellowship and Master’s in Health Research Methodology at McMaster University and received a CIHR New Investigator Award. He was named one of Canada’s Top 40 Under 40.
He has a busy interventional and structural cardiology practice and leads the percutaneous mitral and tricuspid valve programs at HHS. He co-chairs the Canadian Cardiovascular Society Antiplatelet Therapy Guidelines. As program director of interventional cardiology, he has supervised the training over 30 interventional cardiologists in Canada and globally. His research focuses on the role of percutaneous invasive therapies in patients with acute ischemic heart disease, and the evaluation of novel antithrombotic therapies and structural heart interventions.
Dr. Mehta has published over 230 articles and holds peer-review operating grants from the CIHR, Heart and Stroke Foundation of Canada and industry. He has led large-scale trials evaluating antiplatelet therapy in patients with acute coronary syndromes, having been the Principal Investigator of the PCI-CURE study establishing the benefit of clopidogrel in patients with ACS undergoing PCI and the 25,000 patient CURRENT-OASIS 7 trial evaluating aspirin and clopidogrel dosing. He is the Principal Investigator of PREMISE, a Canadian multicenter registry of patients undergoing percutaneous mitral valve repair with the Mitraclip. He has also led landmark trials evaluating pragmatic interventions in ACS, including RIVAL, establishing the benefit of a radial artery versus femoral artery approach in patients with ACS, TIMACS evaluating optimal timing of invasive intervention in patients with ACS and the recently published COMPELTE trial evaluating a strategy of complete revascularization in patients with STEMI and multivessel disease. The COMPLETE trial was recognized by the editors of the New England Journal of Medicine as one of its Most Notable Articles of 2019.
Glen Pearson, BScPhm, PharmD, FCSHP, FCCS
Dr. Glen Pearson is a tenured Professor of Medicine in the Department of Medicine, Division of Cardiology at the University of Alberta (2012-present). He was the Associate Chair of the Health Research Ethics Boards Biomedical & Health Panels from 2012-2020 and is the current Chair of the Trainee Research Access Committee for the Faculty of Medicine & Dentistry. He is the Medical Co-Director of the Cardiac Transplant Clinic at the Mazankowski Alberta Heart Institute. He was appointed by the Minister of Health to serve as a member of the Alberta Expert Committee on Drug Evaluation & Therapeutics Committee since 2011. He has been a member of the Canadian Dyslipidemia Guidelines primary panel since 2009, served as the Vice-Chair for the 2016 CCS Dyslipidemia Guidelines and was the Co-Chair for the 2021 CCS Dyslipidemia Guidelines. He currently teaches in the Cardio-Renal Block of the first Medical Practice course for medical and dental students. He also lectures in cardiovascular pharmacotherapeutics to the both the undergraduate and graduate health professions students at the University of Alberta (PharmD, MD, and MSc/PhD graduate programs). In addition to his clinical and academic responsibilities, Dr. Pearson has an active interest in practice-based research.
Marc A. Pfeffer, MD, PhD
Dr. Marc A. Pfeffer, a graduate of Rockford College in Rockford, Illinois, received both his doctorate in physiology and biophysics and his medical degree from the University of Oklahoma in Oklahoma City. He completed his internship, residency and clinical fellowship at the Peter Bent Brigham Hospital, Harvard Medical School in Boston. Dr. Pfeffer is currently the Distinguished Dzau Professor of Medicine at Harvard Medical School, and Senior Physician in the Cardiovascular Division at the Brigham and Women’s Hospital in Boston. A noted researcher, Dr. Pfeffer, along with his late wife, Dr. Janice Pfeffer, and Eugene Braunwald MD, is credited with introducing the concept that angiotensin-converting enzyme inhibitors (ACEIs) could attenuate adverse ventricular remodelling following myocardial infarction and that this use would result in a prolongation of survival and other clinical benefits. Since this initial discovery, he has had a principal role in several practice-changing clinical outcome trials.
An internationally recognized expert in the field of cardiology, Dr. Pfeffer was recognized by Science Watch as having the most ‘Hot Papers’ (highly cited) in all of clinical medicine and was listed as one of the highly influential biomedical researchers of 1996-2011 in the European Journal of Clinical Investigation. He is the recipient of the William Harvey Award of the American Society of Hypertension, the Okamoto Award from Japan’s Vascular Disease Research Foundation, the American Heart Association Clinical Research Prize and the James B. Herrick Award. The Distinguished Scientist Awards from both the American Heart Association as well as the American College of Cardiology. The Lifetime Achievement Award from both the Heart Failure Society of America and the Heart Failure Association of the European Congress of Cardiology. The Gold Medal Award from the European Society of Cardiology in 2018. Dr. Pfeffer has Honorary Doctoral Degrees from Sahlgrenska Academy and the University of Gothenburg, Sweden and from the University of Glasgow, Scotland.
Josep Rodés-Cabau, MD, PhD
Dr. Josep Rodés-Cabau completed his medical studies at the University of Barcelona, Spain, and a residency in cardiology at the Vall d’Hebron University Hospital of Barcelona, Spain. He did a fellowship in Interventional Cardiology at the Montreal Heart Institute, Montreal, Canada and at the Institut Cardiovasculaire ParisSud, Paris, France. He is currently the director of the Catheterization and Interventional Laboratories of the Quebec Heart and Lung Institute, Quebec, Canada; Associate Professor of Medicine at Laval University, Quebec City, Canada; and Director of Research and Innovation at the Hospital Clinic of Barcelona, Barcelona, Spain. He has developed his research program in the field of interventional cardiology, with special interest in structural heart disease. He holds the Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions (Laval University). He has published 600 articles in peer-reviewed journals, and has an H index of 102 (H index -5 years-: 88). He is among the 1% most cited scientists, and he is currently associate editor of the Journal of the American College of Cardiology.
Robert Rosenson, MD, FACC, FACP, FAHA, FNLA, FACCP
Robert S. Rosenson, MD, is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Director of Metabolism and Lipids for the Mount Sinai Health System, New York, New York. He received his medical degree at Tulane University, New Orleans, Louisiana, and went on to complete his residency in internal medicine at Brigham and Women’s Hospital, Boston, Massachusetts, followed by a fellowship in cardiovascular medicine at The University of Chicago, Chicago, Illinois.
Dr Rosenson is a Fellow of the American College of Cardiology (FACC), American College of Physicians (FACP), College of Chest Physicians (FCCP), Fellow of the American Heart Association (FAHA) Council on Arteriosclerosis, Thrombosis, and Vascular Biology, and the AHA Council on Epidemiology and Prevention, European Society of Cardiology (FESC) and National Lipid Association (FNLA). Dr Rosenson was Global PI of the PLASMA I, PLASMA II, FRANCIS, BANTING, and two phase 2 trials with evinacumab. He is the recipient of numerous awards and honors, including the Ground-Breaking Doctors Award from Chicago magazine, and was named New York Top Doc from 2015 to 2021 and USA Top Doctor in 2019. Dr Rosenson was named recipient of the Simon Dack Award for outstanding scholarship by the Journal of the American College of Cardiology
in 2015, 2016, 2017, 2019 and 2020. The International Academy of Cardiology honored him with the Jan J. Kellerman Memorial Award in 2016 for distinguished contributions in the field of cardiovascular disease prevention. In 2017, UpToDate recognized him for 20 years of Outstanding Contributions as Editor. In 2019, he was awarded the Clinician Educator Award from the National Lipid Association. He was selected by the Univesity of Toronto for the “Great Minds and Great Medicine: Isadore Rosenfeld Visiting Lectureship
He is former co-Editor in Chief for Cardiovascular Drugs and Therapy
, Section Editor on Metabolic Disorders for the Journal of the American College of Cardiology
, and Section Editor on Lipid Disorders for UptoDate
John A. Spertus, MD, MPH, FACC
John Spertus is a cardiologist and the Lauer/Missouri Endowed Chair and Professor of Medicine at the University of Missouri-Kansas City, where he serves as Clinical
Director of Outcomes Research at Saint Luke’s Mid America Heart Institute. He is a graduate of UCSF Medical School and completed his internal medicine, cardiology and health services training at the University of Washington. He has served on numerous national committees for the American College of Cardiology, American Heart Association, American Medical Association, National Quality Forum, Medicare and United Healthcare. His research activities led to his induction into the American Society of Clinical Investigation in 2006 and the Association of University Cardiologists in 2018, his receipt of the AHA Quality of Care and Outcomes Research Council’s Distinguished Achievement Award in 2013, QCOR’s Lifetime Achievement Award in 2015 and being named a Distinguished Scientist in 2018 by the AHA. He has been named by Thompson Reuters as one of the most influential scientists in the world in 2014 and 2015 and among their list of highly-cited authors from 2016-2019.
He founded the Cardiovascular Outcomes Research Consortium and CV Outcomes, a non-profit corporation dedicated to advancing healthcare quality and outcomes research in cardiovascular disease. He is a founder of Health Outcomes Sciences, an information technology company that supports the implementation of evidence-based, personalized medicine in clinical care. Dr. Spertus and his collaborators have published over 800 peer-reviewed articles and hold 9 patents.
Dr. Spertus has devoted his career to improving the quality and patient-centeredness of care. His research focuses on methods for assessing patients’ health outcomes, measuring healthcare quality, and the use of information technology to guide medical decision-making based on risk-prediction models so that treatment can be safer, more cost-effective, evidence-based and patient-centered. He developed the Seattle Angina Questionnaire (SAQ), and the Kansas City Cardiomyopathy Questionnaire (KCCQ), which have both been translated into over 95 languages each and have become the gold standards for measuring patients’ symptoms, function and quality of life in coronary artery disease and heart failure. The KCCQ was the first patient-reported outcomes measure to ever be qualified by the FDA for heart failure. Dr. Spertus has helped design, analyze and interpret the results of numerous clinical trials, including the ISCHEMIA trial, where he led the study’s quality of life component. While he collaborates with basic scientists to illuminate the prognostic significance of genetics and biomarkers on cardiovascular outcomes, his primary focus in the translational research enterprise is at the interface of patient care. Since arriving in Kansas City, Dr. Spertus has continuously supported his research program through extramural funding and currently supports over 18 employees. His group serves as an analytic center for the ACC’s NCDR.
The ability to quantify a patient’s health status has matured rapidly over the past decade and is being tested as a measure of healthcare quality by Medicare and endorsed by ICHOM. These more standardized approaches, which measure symptoms, function, and quality of life in patients with cardiovascular disease, provide the opportunity to use these metrics as outcomes in clinical trials, tools for patient management, selection criteria for disease management programs, methods for quality assessment/improvement, and tools for allowing patients to participate in their medical decision making. The ability of physicians to base treatment decisions on predictive models, and to inform patients’ understanding of treatment options and their predicted outcomes, represents a paradigmatic shift in care that has the potential to significantly improve its value to patients and society.
Anthony Tang, MD, FRCPC
Dr. Anthony Tang is Professor of Medicine and Professor of Epidemiology & Biostatistics at Western University and Adjunct Professor of Medicine in the Faculty of Medicine at the University of Ottawa. Dr Tang is presently Staff Electrophysiologist Division of Cardiology for the London Health Sciences Centre and Chair of Cardiovascular Population Health. He obtained his MD from the University of Toronto and his clinical training in internal medicine and cardiology at the University of Ottawa. Dr. Tang obtained a Heart and Stroke Research Fellowship to receive electrophysiology research training at Duke University Medical Centre. He is member of Ontario Medical Association, Canadian Cardiovascular Society, Canadian Heart Rhythm Society, and Heart Rhythm Society (Fellow).
Dr. Tang’s clinical and research expertise is on the diagnosis and treatment of patients with cardiac arrhythmia, particular in heart failure patients. He has conducted multi-national, multicentre clinical trials for more than 20 years. The research on the addition of CRT to Implantable Cardioverter Defibrillator (ICD) and medical therapy demonstrated a reduction of total mortality and hospitalization for Heart Failure (HF) in ambulatory heart failure patients. (NEJM 2010;363(25):2385-95). This study results changed the treatment strategy of heart failure patients with compromised LV function and electrical dyssynchrony. Dr. Tang currently has two CIHR grants to conduct research that examines treatment options for patients in Atrial fibrillation with heart failure. Currently, he is the Scientific Director & CEO for the Canadian Arrhythmia Network (CANet), which is funded by the Network of Excellence (NCE) from 2015-20.
Dr. Tang is an internationally renowned researcher, has been an invited speaker at national and international meetings, and is a peer reviewer for scientific journals, as well as grant reviewer. His publication record includes over 140 peer reviewed papers, 5 book chapters and over 270 abstracts.
Jean-Francois Tanguay, MD, FRCPC, FCCS, FACC, FAHA, FESC
Dr. Tanguay is an expert in Interventional Cardiology with a strong interest in translational research. He is involved in undergraduate and postgraduate medical training and CME education. Dr. Tanguay is Director of the Interventional Cardiology Division at the MHI and Clinical Cardiologist, combining work in the emergency room, the coronary care unit, the outpatient clinic and the catheterization laboratory (1995-ongoing). He is Director of the MD-PhD and Interventional Cardiology Training Programs and professor at the Faculty of Medicine of the Université de Montréal.
His research is focus on understanding the interactions between platelets, leukocytes and endothelial cells in order to improve vascular healing. Dr. Tanguay’s investigations brought promising discoveries related to 17beta-estradiol and the specific contribution of estrogen receptors in vascular healing. During his research fellowship, Dr Tanguay studied the early prototypes of bioresorbable drug eluting stents platforms in pre-clinical and thrombosis models. With his colleagues at MHI, he performed the first coronary implantation of a drug-eluting bioresorbable scaffold (ABSORBTM) in North-America.
He has authored and co-authored more than 300 scientific publications, abstracts and books chapters. His current research interests focus on improving vascular healing, stabilizing vulnerable plaque and reducing restenosis.
George Thanassoulis, MD
Dr. Thanassoulis is the Director of Preventive and Genomic Cardiology at the MUHC and an Associate Professor of Medicine at McGill University. His clinical interests are in cardiovascular prevention, dyslipidemia (specifically lipoprotein[a]) and premature coronary artery disease. He currently runs the MUHC Family Heart Clinic for patients with premature CAD and their families with the goal of optimizing their preventive care. His research interests are in the genetics of aortic valve stenosis where he leads an international consortium investigating the role of genomic variation in this disease. He is also working on developing new approaches to optimize cardiovascular prevention in young individuals. He is the co-chair of the 2021 CCS Dyslipidemia Guideline Committee.
Richard Whitlock, MD, PhD, FRCSC
Dr. Whitlock is a Professor of Surgery at McMaster University and a practicing cardiac surgeon at Hamilton Health Sciences. He is a lead investigator at the Population Health Research Institute and the principal investigator of the LAAOS III trial, along with co-principal investigator Dr. Stuart Connolly. Dr. Whitlock holds the Canada Research Chair in Cardiovascular Surgery and a career award from the Heart and Stroke Foundation of Canada.
Through the multinational studies that he has led, which include SIRS, TRICS III, VISION Cardiac, and LAAOS III, he has established a network of over 130 collaborating cardiac surgical centres in 32 countries.
Gloria Y. Yeh, MD, MPH
Gloria Yeh, MD, MPH is Associate Professor of Medicine at Harvard Medical School (HMS), Director of Clinical Research at the Osher Center for Integrative Medicine at HMS and Brigham and Women’s Hospital, and Director of the NIH T32-funded HMS Research Fellowship in Integrative Medicine. Her research program is based in the Division of General Medicine at Beth Israel Deaconess Medical Center, where she also serves as the Division’s Director of Mind-Body Research. Dr. Yeh is an internationally recognized leader in the field of mind-body medicine, including Tai Chi, yoga, and meditation. Her research has investigated the impact of mind-body movement interventions on physiological, psychosocial, and behavioral outcomes in complex chronic illness. Dr. Yeh also serves as a member of the Academic Consortium for Integrative Medicine and Health and on the NIH National Advisory Council for Complementary and Integrative Health.
Shelley Zieroth, MD, FCCS, FHFSA (hon), FESC, FACC, FHFA, FRCPC
Dr. Shelley Zieroth joined the Section of Cardiology at St. Boniface Hospital in Winnipeg in July 2006. She is currently a Professor in the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
Dr. Zieroth attended medical school at the University of Manitoba and went on to train in Internal Medicine and Cardiology at the same centre. She completed her Postdoctoral Clinical Fellowship, specializing in Advanced Heart Failure and Cardiac Transplant, at Toronto General Hospital.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. Her area of research examines the efficacy of new treatments including food derived bioactives, in heart failure. She is the Immediate Past President of the Canadian Heart Failure Society and on the Canadian Cardiovascular Society Primary Panels for both the Heart Failure and Heart Transplant Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. Her current passion is working with national and provincial patient advocacy groups and primary care to operationalize hub and spoke models of heart failure care.
Dr. Zieroth is actively engaged in Social Media and promotes #cardiotwitter for its rapid access to clinical trial data, publications, and free online access to medical education. It is through this engagement Dr. Zieroth has become recognized as a global supporter and sponsor of women in medicine and cardiology.